Infinity Pharmaceuticals Inc (NASDAQ:INFI) – Infinite possibilities on the Lymphoma horizon

Posted by Lynn Eisler June 5, 2013 0 Comment 1221 views

On Tuesday, Infinity Pharmaceuticals Inc (NASDAQ:INFI) announced updated data from its ongoing Phase-1 data study of its potent oral inhibitor, IPI-145. The study is being conducted on patients who are suffering from relapsed/refractory lymphoma. This is a group of blood cancers or hematologic malignancies that have the potential to be fatal. The study-data showed that IPI-145 has been tolerated well and is clinically active in patients suffering from T-cell or B-cell lymphomas. The study-findings were presented on Tuesday at the 2013 American Society of Clinical Oncology, Annual Meeting.

Some facts…

Over the past 40 years, a substantial amount of progress has taken place in developing treatments for hematologic malignancies. Today, it is possible to cure patients suffering from Hodgkin’s disease as well as some patients suffering from high-grade, non-Hodgkin’s lymphoma. There is also an improvement in prognosis of patients suffering from acute promyelocytic leukaemia. To a certain extent, those suffering from myeloid leukemias and acute lymphoblastic have also been benefited. Though all this progress seems heartening, the fact of the matter is that a large percentage of those who suffer from hematologic malignancy are compelled to live with it- at this point, there really is no definite cure for it.

It has not yet been established whether treatment strategies that are based on certain prognostic parameters like cytogenetics can actually change the course of this disease. In a majority of patients suffering from indolent lymphomas, there is no immediate cure in sight. There has been no change in the 9-10 years median survival, over the last several decades.

The light at the end of the lymphoma tunnel

Despite this, there has been a paradigm change in the development of therapeutics over the last few years. Molecular remissions are now achievable with the use of

recombinant monoclonal antibodies and new cytostatic drugs. What needs to be seen is whether this actually translates into either prolonged survival or even a cure. Hodgkin’s disease is now curable either with chemotherapy, radiotherapy or a combination of both, depending on what stage the disease has progressed into. Similarly, with other hematologic malignancies as well, it is important for companies such as Infinity Pharmaceuticals Inc (NASDAQ:INFI) to focus on preserving the quality of life in patients who suffer from this currently incurable disease.

About Lynn Eisler

Lynn Eisler is a national news reporter focusing on economic issues, data analysis and the financial health of state and local governments. Lynn has been honored with the H.L. Mencken Award for Investigative Reporting, the Champion of Justice Award for reporting on the drug war, and the John Hancock Award for business reporting. Lynn was also a Knight Medical School Fellow at the University of Michigan.

View all post by Lynn Eisler Visit author's website

Write Your Comment